Invivoscribe’s Virtual Workshop | AMP 2020 Clinical Utility of NGS in Lymphoid Malignancies including Minimal Residual Disease (MRD) testing. Artificial Intelligence (AI) and other Data Science Applications in Molecular Pathology.
AMP – Invivoscribe Virtual Workshop Featured Presenters Yury Monczak, Ph.D / Ryan J. Schmidt, MD, PhD
Next Generation Analysis in CLL and Other Malignancies presented by Prof. Dr. Markus Tiemann – Institute for Hematopathology Hamburg, Germany
EHA – (3) Part Video Series
Invivoscribe’s Symposium at EHA 2019 | Amsterdam, The Netherlands | June 13, 2019 Molecular Clinical Assessment and Monitoring of Hematologic Malignancies: B- and T-Cell Clonality, SHM and MRD Detection.
Invivoscribe – EHA 2019 Video Series Part (1) of 3 Featured Speaker Marleen Bakkus
Featured Speaker: Dr. Bradley Patay, Invivoscribe, Chief Medical Officer
AMP – (4) Part Video Series
Invivoscribe – AMP 2019 | Baltimore | November 6, 2019 A national reference laboratory experience using LymphoTrack® Assays for IGHV somatic hypermutation in CLL and the utilization of FLT3 PCR testing as a useful adjunct to myeloid NGS for AML. Utilization of LymphoTrack® Next-Generation Sequencing Assays for Pre- and Post- Treatment Monitoring Studies.
Invivoscribe – AMP 2019 Video Series Part (1) of 4 Featured Speaker Bevan Tandon M.D.
Invivoscribe – AMP Global 2019 (4) Part Video Series Invivoscribe’s Symposium at AMP Global 2019 – Hong Kong, May 16th
Topic: NGS Solutions for the Assessment of Clonality and Somatic Hypermutation (SHM) in Hematologic Malignancies.
Analysis of IGHV Mutational Status, T-Cell Clonality and MRD by NGS.
Featured Speaker: Oliver Giles Best – CLL Research Laboratory, Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, Sydney, Australia
Invivoscribe – AMP Global 2019 Video Series Part (4) of 4 Featured Speaker Piers Blombery